I think its easy for folks to forget that COVID was a bonus indication. I remain hopeful that there will be an opportunity with COVID, but for the sake of argument lets say we've missed the opportunity.

This does not change the long term potential for Leronlimab, but does change the short term prospective. It likely means more dilution, which is meaningful, but not unexpected. After all, it is the reason why we authorized the additional shares.

I agree that the company is learning, and our new hires should propel CYDY across the HIV finish line.

The fact remains, that an HIV approval will bring revenue and stop dilution. It will also grease the wheels for all future indications.